S. Gunther et al., Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure, J HEPATOL, 30(5), 1999, pp. 749-754
Background/Aims: Nucleoside analogues such as lamivudine and famciclovir ar
e potent drugs for treatment of chronic hepatitis B virus infection, Breakt
hrough infections during lamivudine therapy are associated with mutations i
n the YMDD motif and putative B region of the HBV polymerase. This study in
vestigated whether failure of famciclovir therapy is also associated with p
resence or emergence of particular mutations in the HBV polymerase.
Methhods: We analyzed longitudinally the sequence of the priming and polyme
rase domain in seven patients with primary non-response to therapy and two
patients with a breakthrough during therapy. Two patients who responded to
therapy served as a control.
Results: The YMDD motif and the B region were conserved in all isolates. V-
->I changes at position 555 just downstream of the YMDD motif were observed
before and during therapy in a virus subpopulation of two patients with a
primary non-response. In patients with a breakthrough, 378-V-->I and 424-N-
->D mutations emerged in the N terminal part of the polymerase domain durin
g follow-up. Lamivudine rescue therapy initiated in four patients, includin
g a patient infected with YMDD(555-V-->I) variants, efficiently reduced vir
emia,
Conclusions: These data indicate that failure of famciclovir therapy can oc
cur independently of mutations in the YMDD motif or B region of the HBV pol
ymerase and provide a rationale for rescue therapy with lamivudine.